RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

BACKGROUND: 20–60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Oza, Bhavna, Frangou, Eleni, Smith, Ben, Bryant, Hanna, Kaplan, Rick, Choodari-Oskooei, Babak, Powles, Tom, Stewart, Grant D., Albiges, Laurence, Bex, Axel, Choueiri, Toni K., Davis, Ian D., Eisen, Tim, Fielding, Alison, Harrison, David, McWhirter, Anita, Mulhere, Salena, Nathan, Paul, Rini, Brian, Ritchie, Alastair, Scovell, Sarah, Shakeshaft, Clare, Stockler, Martin R., Thorogood, Nat, Parmar, Mahesh K.B., Larkin, James, Meade, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520913/
https://www.ncbi.nlm.nih.gov/pubmed/34538402
http://dx.doi.org/10.1016/j.cct.2021.106482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520913/
https://www.ncbi.nlm.nih.gov/pubmed/34538402
http://dx.doi.org/10.1016/j.cct.2021.106482

Ejemplares similares